Major Arthritis Trial Launched in Scotland
Scotland chosen to lead a £26m clinical trial for arthritis sufferers
SCOTLAND, UK, December 16, 2007-A £26m study of medicines to treat the pain of arthritis, which reinforces Scotland’s place as a leader in the delivery of major clinical trials, was launched today.
The SCOT Trial, (Standard Care versus Celecoxib Outcome Trial), will compare different types of treatment for arthritis-a series of conditions which affects around nine million people in the UK.
The trial compares traditional non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and diclofenac, with a newer NSAID called Celecoxib. Both types of NSAID are prescribed for the treatment of arthritis, but doctors want to know how the newer NSAID Celecoxib compares with the older NSAID in patients with arthritis in terms of long-term safety.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
